Evommune Income Statement (2024-2026) | EVMN

Income Statement Sep2024 Dec2024 Mar2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter) 3.00M10.00M
Operating items
Research & Development (Quarter) 13.29M17.83M14.36M19.64M20.40M17.32M
Selling, General & Administrative (Quarter) 3.23M3.62M3.67M3.69M9.31M6.63M
Operating Expenses (Quarter) 16.52M21.45M18.03M23.33M29.72M23.95M
Operating Income (Quarter) -16.52M-21.45M-15.03M-13.33M-29.72M-23.95M
EBIT (Quarter) -16.52M-21.45M-15.03M-13.33M-29.72M-23.95M
Non-operating items
Interest & Investment Income (Quarter) 0.62M0.73M0.61M0.86M1.44M2.28M
Other Non Operating Income (Quarter) 0.60M0.73M0.47M0.85M1.44M2.28M
Non Operating Income (Quarter) 0.60M0.73M0.47M0.85M1.44M2.28M
Net income details
EBT (Quarter) -15.92M-20.73M-14.43M-12.47M-28.27M-21.67M
Profit After Tax (Quarter) -15.92M-20.73M-14.56M-12.47M-28.27M-21.67M
Income from Continuing Operations (Quarter) -15.92M-20.73M-14.43M-12.47M-28.27M-21.67M
Consolidated Net Income (Quarter) -15.92M-20.73M-14.43M-12.47M-28.27M-21.67M
Income towards Parent Company (Quarter) -15.92M-20.73M-14.43M-12.47M-28.27M-21.67M
Net Income towards Common Stockholders (Quarter) -15.92M-20.73M-14.43M-12.47M-28.27M-21.67M
Additional items
EPS (Basic) (Quarter) -10.47-14.60-9.48-8.0715.14-0.64
EPS (Weighted Average and Diluted) (Quarter) -10.47-14.60-9.48-8.0715.14-0.64
Shares Outstanding (Weighted Average) (Quarter) 1.50M1.51M1.53M1.54M6.14M33.67M
Shares Outstanding (Diluted Average) (Quarter) 1.52M1.51M1.53M1.55M6.14M33.67M
EBITDA (Quarter) -16.52M-21.45M-15.03M-13.33M-29.72M-23.95M
Interest Expenses (Quarter) 0.02M-0.00M0.01M0.01M0.00M